Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BAL0891 |
| Trade Name | |
| Synonyms | BAL-0891|BAL 0891 |
| Drug Descriptions |
BAL0891 inhibits both TTK (MPS1) and PLK1, which potentially leads to disrupted cell cycle progression and decreased tumor cell proliferation (Cancer Res (2022) 82 (12_Supplement): 5645). |
| DrugClasses | MPS1 Inhibitor 27 PLK1 Inhibitor 18 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BAL0891 | BAL0891 | 0 | 1 |
| BAL0891 + Carboplatin | BAL0891 Carboplatin | 0 | 0 |
| BAL0891 + Paclitaxel | BAL0891 Paclitaxel | 0 | 1 |
| BAL0891 + Tislelizumab | BAL0891 Tislelizumab | 0 | 1 |